Neurocrine Biosciences News and Activities

Presence

Neurocrine Biosciences develops and sells medicines for neurological, endocrine, and psychiatric disorders. Its products and research services support patients, healthcare providers, and partners in the biotechnology and pharmaceutical markets.

Neurocrine Biosciences products and services overview:

Neurology medicines
Endocrine therapies
Psychiatric treatments
Drug research
Clinical development
Commercial medicines

Revenue: ~$2 billion

Employees: 1,900

Headquarters: San Diego, United States (USA)

Neurocrine Biosciences is one of the...

Neurocrine Biosciences is a company listed under the stock ticker NBIX (US).

Acquisition, funding and merger involving Neurocrine Biosciences.

Neurocrine Biosciences has acquired Soleno Therapeutics (posted on May 18 2026).
Neurocrine Biosciences has announced the acquisition of Soleno Therapeutics (posted on April 7 2026).

Executives

View the org chart displaying its 58 main executives

Most searched biographies at Neurocrine Biosciences

Popular executive movements at Neurocrine Biosciences

Andrew Ratz, who was Senior Vice President, Drug Development, Delivery and Device, is promoted to Chief Technical Operations Officer (posted on March 18 2026).
Mike Sibley has joined the company as Senior Vice President and General Manager, Neuropsychiatry Franchise (posted on October 7 2025).

Create your alert
to follow the executive moves at Neurocrine Biosciences.